Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients ...

When a biotech company announces positive Phase 3 trial results or receives FDA approval, the market reaction is often immediate and substantial. This is not just speculation. These milestones ...

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.

The financing uses a single-asset SPV, allowing BioAtla to fund a pivotal study without a broader equity raise. ・BioAtla ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

The U.S. Space Force has selected SpaceX and United Launch Alliance to perform the first seven launches under the National Security Space Launch Program, or NSSL, Phase 3 Lane 2 contracts, Breaking ...

Roche has installed “stronger gates” to ensure that drug candidates only make it into phase 3 trials if they have a high likelihood of success, CEO Thomas Schinecker has revealed. Pointing to a slump ...

Theriva Biologics ( ($TOVX) ) just unveiled an update. On December 29, 2025, Theriva Biologics reported that it received positive Scientific ...

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

Ambros Therapeutics launches with $125M to advance neridronate, a non-opioid therapy for CRPS-1. See how this Phase 3-ready ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The study, Step-Up HS, will evaluate Rinvoq ...

SE stock is rated Hold due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART. Click here for more on ARGX.